Regentis Biomaterials Ltd. (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC, its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Its lead product GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process.
The company addresses a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is currently available. This highlights the potential impact of GelrinC as a novel solution for a significant unmet medical need. For leaders in business and technology, the implications extend beyond clinical benefits: successful commercialization could establish a new standard in orthopedic regenerative medicine and open avenues for similar hydrogel-based therapies in other tissue repair applications.
The European training program represents a critical milestone in Regentis’ go-to-market strategy. By investing in surgeon education and Centers of Excellence, the company aims to build confidence and competence among practitioners, which is essential for adoption of new medical technologies. The initiative also signals readiness to scale manufacturing and distribution networks in Europe, potentially accelerating revenue generation and market penetration.
For investors and industry observers, the progress of GelrinC’s commercial launch will be a key indicator of Regentis’ ability to execute in a competitive orthopedic landscape. The company’s focus on a cell-free, off-the-shelf product could differentiate it from existing cell-based therapies, offering advantages in cost, logistics, and ease of use. As the training program unfolds, stakeholders will watch for updates on surgeon recruitment, clinical outcomes, and regulatory milestones.
For more information, visit the company’s newsroom at https://ibn.fm/RGNT.
